Prognostic factors for GEM + nab-PTX combination therapy in elderly patients with pancreatic cancer.doi:10.1200/JCO.2024.42.3_suppl.678... K Watabe,I Ohno,M Sakai,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2024年 Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine ...
678#Background:Japanese Clinical Practice Guidelines for Pancreatic Cancer 2022 recommends gemcitabine (GEM) + nab-paclitaxel (nab-PTX) therapy (GnP regimen) as the first line chemotherapy for elderly patients with pancreatic cancer. In Japan, it is reported that about 69% of pancreatic cancer ...
O2-2-2A multicenter retrospective study of GEM+nab-PTX or FOLFIRINOX in metastatic pancreatic cancer patients: NAPOLEON studyanorexia nervosaalopeciachemotherapy regimenneutropeniadiarrheafatiguegemcitabinebrachial plexus neuritisexanthemanauseaBackground Gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX) ...
A case of effective response to Gem+nab-PTX therapy for pancreatic cancer with multiple liver metastasesA 78-years old man began to suffer from frequent vomiting, since he had eaten a dried persimmon three days ago. He had no abdominal surgery history. He came to vomit many times, so he ...
P-385CanStem111P trial: A phase III study of napabucasin plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC)Pancreatic adenocarcinoma is a rare tumor with a very poor outcome. Even with surgery, 5-year overall survival is ...
Radiographic and pathological findings of resected pancreatic cancer after GEM + nab-PTX therapydoi:10.1016/j.hpb.2018.06.2175S. KawakatsuY. InoueY. MiseT. IshizawaA. SaiuraHPB
Methods Chemo-nave stage IIIB/IV or postoperative recurrent SCC pts were randomly assigned to receive either cisplatin (80 mg/m2) on day 1 plus gemcitabine (1000 mg/m2) on days 1, 8 every 3 weeks or CBDCA (AUC 6 mg/ml/min) on day 1 plus nab-PTX (75 mg/m2) on days 1, 8, ...
P1.01-08 Randomized Phase II Trial of CBDCA+nab-PTX vs CDDP+GEM in Patients with Chemo-Nave Squamous Cell Lung Cancer: NJLCG1302doi:10.1016/j.jtho.2019.08.723T. HaradaY. KawashimaY. FujitaT. NakagawaK. WatanabeN. MorikawaK. Takamura...
Mobilization of Circulating Tumor Cells after Short- and Long-Term FOLFIRINOX and GEM/nab-PTX Chemotherapy in Xenograft Mouse Models of Human Pancreatic Cancer. Cancers. 2023; 15(22):5482. https://doi.org/10.3390/cancers15225482 Chicago/Turabian Style Ito, Yukako, Shinji Kobuchi, Amiri Kawakita...
Background GEM plus nab-PTX (GnP) and FOLFIRINOX (FFX) have been shown to improve overall survival for advanced pancreatic cancer patients. However, clinical utility of C-reactive protein/albumin ratio (CAR) as prognostic factor for the patients treated with GnP or FFX remains unclear. We ...